載入...
KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer
KRAS is the most frequently mutated oncogene in non‐small cell lung cancer (NSCLC). However, the prognostic role of KRAS mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS mutation status will have the most prominent effect and...
Na minha lista:
| 發表在: | Int J Cancer |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5299512/ https://ncbi.nlm.nih.gov/pubmed/27859136 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.30509 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|